Patient Journey Research GCC

What patient journey research is and why it matters in GCC

Patient journey research is the systematic mapping and analysis of the sequence of experiences, decisions, and touchpoints a patient with a specific medical condition moves through — from the first awareness that something is wrong, through help-seeking and diagnosis, specialist referral, treatment selection, initiation, and ongoing adherence or persistence. In its richest form, it integrates the patient's subjective experience and emotional state at each stage with the structural and system-level factors that shape their pathway.

For pharmaceutical teams launching in GCC markets, patient journey research matters because it reveals the actual size and structure of the addressable patient population — which is often smaller and more fragmented than epidemiological prevalence data would suggest. A condition with 18% adult prevalence in KSA or 19% in UAE is not generating equivalent commercial opportunity if 40–50% of those patients remain undiagnosed, another 20–25% are diagnosed but not treated, and a further 15% are treated but not persistent beyond 90 days. Journey research maps exactly where patients are lost and why.

Beyond market sizing, journey research provides the evidence base for medical education strategy (which diagnosis gaps need HCP-level intervention?), patient support programme design (what adherence barriers need addressing at treatment initiation?), and formulary and access argumentation (what patient burden narrative supports reimbursement priority?). It is both a pre-launch planning tool and a lifecycle evidence asset.

GCC-specific journey features

Several structural characteristics of GCC healthcare systems create journey dynamics that differ from European or North American norms and must be captured explicitly in research design.

Late diagnosis culture. In chronic conditions with gradual symptom onset — type 2 diabetes, hypertension, certain cancers, and many autoimmune diseases — GCC patients often present for formal diagnosis only when symptoms become disabling or acute. Cultural factors contribute: stoicism, reluctance to seek medical attention for non-acute symptoms, and a tendency to manage early symptoms through dietary or religious practices before engaging the healthcare system. In KSA, research consistently shows that a significant proportion of newly diagnosed type 2 diabetes patients have had detectable glycaemic abnormality for 3–7 years before diagnosis. This creates a diagnosis gap that is commercially significant — treatments targeting early intervention cannot reach patients who are not in the system.

High specialist referral barriers. The GCC healthcare system is built around hospital-based specialists rather than primary care gatekeepers in the way European systems are structured. In KSA, the MOH primary care system exists but has historically been under-resourced and lacks the continuity of care model that enables reliable chronic disease management. Patients with chronic conditions often seek specialist care directly but face queuing and access barriers within the government hospital system — referral wait times of 4–12 weeks for government specialist appointments are common for non-urgent conditions. This creates a gap in the journey between initial symptom recognition and specialist engagement that is longer and more variable than in European markets.

Dual government and private care pathways. Many GCC patients — particularly in KSA and UAE — navigate both government and private care simultaneously, exploiting the complementary strengths of each. The government sector offers subsidised or free medicines but has longer wait times and less personalised interaction. The private sector offers faster access and more time with physicians but carries out-of-pocket or insurance costs. A patient's journey may involve initial diagnosis in a private clinic, specialist follow-up in a government hospital (to access subsidised medicines), and pharmacy management back in a private pharmacy. These hybrid pathways create complexity for commercial teams — which sector touchpoints matter most for prescribing behaviour, product recommendations, and patient education?

Family and caregiver involvement. Health decision-making in GCC is frequently collective rather than individual. In conditions affecting older patients, or in contexts where cultural norms around patient autonomy are more limited — particularly for female patients in traditional households — family members play a direct and active role in decisions about whether to seek care, which physician to visit, whether to fill a prescription, and whether to continue a treatment regimen. Journey research that interviews only the patient without capturing the caregiver perspective will systematically under-record a major source of pathway friction and decision influence. BioNixus designs GCC journey studies to include caregiver interviews as a standard stakeholder segment.

Key disease areas for GCC patient journey research

Certain disease areas have particularly rich journey research value in GCC due to the combination of high prevalence, complex pathway dynamics, and significant commercial opportunity.

Diabetes and metabolic disease. Type 2 diabetes adult prevalence is estimated at approximately 18–19% in both KSA and UAE — among the highest rates globally — with pre-diabetes prevalence adding another 10–15%. The treatment landscape encompasses oral antidiabetic agents, GLP-1 receptor agonists, SGLT-2 inhibitors, insulin, and combination therapies. The journey for a newly diagnosed patient is complex: initial GP management, specialist referral decision (diabetologist vs. endocrinologist vs. GP-continued management), education provision, device choice for insulin users, and long-term adherence to often complex regimens. Journey research here maps the critical branch points that determine whether patients receive optimal therapy.

Oncology. Cancer diagnosis and management pathways in GCC have unique characteristics. Late-stage presentation is a persistent challenge — many GCC cancer patients are diagnosed at stage III or IV, partly due to lower screening programme uptake compared with Europe or North America, and partly due to the late-diagnosis culture described above. The journey from symptom recognition to oncology consultation can involve multiple GP and general medicine encounters before referral, particularly in KSA's tiered government hospital system. For pharma teams launching oncology products in GCC, understanding these diagnosis gaps and the referral-to-treatment timeline is critical for realistic launch uptake projections.

Cardiovascular disease. Cardiovascular disease is the leading cause of death across most GCC countries, with hypertension and dyslipidaemia as the predominant risk drivers. The patient journey for cardiovascular risk management often begins in primary care or occupational health settings (particularly in KSA's large corporate employer health programmes) but transitions to cardiology for established disease. Adherence to long-term cardiovascular medications is a well-documented challenge in GCC — rates of statin discontinuation after 12 months have been reported as high as 50–60% in some GCC cohort studies, substantially higher than European benchmarks. Journey research in this area quantifies and maps the specific adherence barrier structure.

Respiratory disease. Asthma and COPD represent significant but historically undertreated disease areas in GCC. High rates of smoking in male GCC populations, alongside occupational dust and chemical exposures, drive a substantial COPD burden. Asthma management pathways often involve over-reliance on short-acting rescue inhalers and under-prescription of maintenance therapy. The journey from symptom recognition to appropriate inhaler therapy involves multiple prescribing decisions where journey research can identify intervention opportunities.

Stakeholder mapping in GCC patient journey research

A comprehensive GCC patient journey study maps the perspectives and roles of multiple stakeholder groups across the pathway. Each stakeholder type provides a different lens on the journey and different data type.

Patients provide the experiential journey narrative — what they felt, believed, and decided at each stage, and what barriers or facilitators they encountered. Qualitative depth interviews with patients (8–15 per country for qualitative saturation) are the primary method, supplemented by online diaries for real-time journey capture. Recruiting patients through HCP referral (snowball from treating physician) or patient support organisations provides higher quality participants than open recruitment.

Caregivers provide the family decision-making perspective. For conditions affecting older patients, patients with limited health literacy, or conditions with significant functional impact (severe asthma, advanced cancer, insulin-dependent diabetes), caregiver interviews often reveal as much pathway-relevant data as patient interviews. BioNixus designs GCC journey studies with a dedicated caregiver interview quota of 4–8 per country alongside the patient interview programme.

General practitioners and primary care physicians are the journey gatekeepers for most non-emergency conditions. GP IDIs (5–8 per country) map the referral decision criteria, the diagnostic barriers at primary care level, and the GP's understanding of what specialist care offers that they cannot provide.

Specialist physicians provide the detailed treatment decision framework — what information they have when they first see a patient, how they select therapy, and what support or monitoring they provide. Specialist IDIs (6–10 per country) are the core clinical data source for the treatment initiation and management stages of the journey.

Pharmacists provide a window into treatment initiation friction, adherence support capability, and the interaction between prescribed therapy and actual dispensing. Community pharmacist interviews (4–6 per country) are particularly valuable for oral therapies and self-administered injectables.

Payers provide the system-level perspective on access barriers, coverage policies, and formulary restrictions that shape which treatments patients can access and at what cost. Payer interviews (3–5 per country for GCC journey research) complete the stakeholder picture and are essential when the journey includes a reimbursement or cost barrier stage.

Touchpoint analysis: mapping the end-to-end GCC journey

GCC patient journey research structures the touchpoint sequence across eight key stages, each of which can be analysed for friction severity, stakeholder involvement, and intervention opportunity.

Stage 1 — Symptom awareness. When and how does the patient first notice that something is abnormal? What does the symptom mean to them? Do they associate it with a medical condition or attribute it to fatigue, diet, or ageing? GCC research consistently shows that symptom interpretation is shaped by cultural health beliefs, family normative comparisons ("everyone in my family has this"), and low awareness of early-stage disease presentations.

Stage 2 — Help-seeking decision. The decision to seek medical care is not automatic — it is influenced by perceived severity, social pressure (family encouragement or discouragement), access costs, and stigma. In GCC, this decision is often delayed relative to Western norms for non-acute conditions. The help-seeking stage is where the largest diagnosis delays typically originate.

Stage 3 — First medical contact. Who does the patient see first? GP, emergency department, occupational health, or a private specialist? In UAE, self-referral to specialists is common given insurance coverage and easy access. In KSA, the MOH gatekeeper model means first contact is more likely to be a primary care physician within the government system. The choice of first contact determines the subsequent referral pathway.

Stage 4 — Diagnosis. The diagnostic stage maps the time and touchpoints between first medical contact and confirmed diagnosis. Referral-to-diagnosis gap analysis is a key output — how many weeks or months between first symptom presentation and confirmed diagnosis? What investigations were performed and in what sequence? Were there missed opportunities for earlier diagnosis?

Stage 5 — Specialist referral. For conditions requiring specialist management, the referral process is a critical journey stage. Referral wait times, the quality of information transferred in the referral letter, and patient expectations of what specialist care will involve all affect the diagnosis-to-treatment-initiation timeline. Delays at this stage are a significant source of commercial opportunity loss.

Stage 6 — Treatment selection and initiation. This is the primary commercial stage — the therapy selection decision, formulary constraints that shape which treatments are available at which cost, patient education at initiation, and the first-fill experience. Research here maps prescribing criteria, the role of treatment guidelines vs. formulary vs. personal experience, and what information the patient receives at initiation.

Stage 7 — Adherence and monitoring. The 90-day and 12-month adherence stage captures whether patients continue treatment as prescribed, what drives early discontinuation, what the monitoring cadence looks like, and what support (if any) the patient receives. In GCC, this is where many therapy brands lose a disproportionate share of their patient base relative to European benchmarks.

Stage 8 — Persistence and long-term management. The long-term management stage captures disease progression, regimen intensification decisions, and the patient's accumulated experience of the healthcare system. It is also where secondary complications and co-morbidity management increasingly dominate the healthcare interaction.

Arabic-language qualitative research for patient journey work

Qualitative patient research in GCC requires Arabic as the primary interview language in most markets. Patients in KSA, Kuwait, Qatar, and Bahrain predominantly prefer Arabic for healthcare discussions, and Gulf-dialect Arabic — which differs in vocabulary and register from Egyptian or Levantine Arabic — is the appropriate conversational register for KSA and Gulf patient interviews. BioNixus deploys Gulf Arabic-speaking qualitative researchers who are trained in health psychology interviewing techniques and who can discuss sensitive topics (disease impact, stigma, financial hardship, family dynamics) with the cultural competence required for authentic responses.

Topic guide development for Arabic patient research requires specific considerations. Direct questions about sensitive disease experiences (e.g., impact on sexual function in diabetes, family burden in oncology, social limitations in severe respiratory disease) require indirect framing in Arabic to avoid social desirability bias and premature interview termination. Narrative interviewing techniques — asking patients to "tell the story" of their illness rather than answering direct structured questions — tend to produce richer and more authentic data in GCC cultural contexts than highly structured closed probing.

Patient consent in Gulf Arabic is mandatory for all GCC patient research, and the consent process itself must be conducted in the patient's preferred language by the interviewer, not simply presented as a document. For patients with low health literacy or who are unfamiliar with research participation, the consent explanation should be supplemented by a simple verbal summary of what participation involves and what will happen to their information.

Cost ranges and timelines

Patient journey research in GCC is inherently more complex to field than HCP research, due to patient recruitment logistics, ethics requirements, and the multi-stakeholder design. Cost and timeline ranges below cover full qualitative journey programmes spanning three GCC markets with multiple stakeholder types.

Single market qualitative journey study (KSA or UAE), 10–15 patient IDIs + 6–8 HCP IDIs + 3–5 caregiver IDIs: $45,000–$75,000 fieldwork cost; 6–8 weeks from brief to raw data. Three-market GCC journey study (KSA, UAE, Kuwait or Qatar), equivalent design per market: $120,000–$180,000; 8–12 weeks. Multi-method journey study with online diary component (4–6 weeks diary run) plus qualitative IDIs: $130,000–$200,000; 14–18 weeks total. Full journey programme with payer interviews and medical chart review added: $150,000–$220,000; 12–16 weeks.

These ranges exclude analysis, journey mapping, and reporting, which is typically an additional $25,000–$50,000 for a three-market multi-stakeholder study depending on depth of output required.